Sun Pharmaceutical Industries announced its Q1FY25 results on Thursday, reporting a significant 40.2% year-on-year (YoY) growth in consolidated net profit, reaching ₹2,835.62 crore compared to ₹2,022.54 crore in the year-ago quarter. This impressive surge underscores the company's strong performance and strategic initiatives.

The revenue from operations for the first quarter of the current fiscal increased by 6%, totaling ₹12,652.7 crore, up from ₹11,940.84 crore in Q1FY24. This growth highlights Sun Pharma's robust operational capabilities and market presence.

Segment Performance

US Formulation Sales: Fell by 1% to $466 million, accounting for 31.1% of total consolidated sales.

India Formulation Sales: Increased by 16.4% to ₹4,144.5 crore, representing 33.1% of total consolidated sales.

Emerging Markets Sales: Grew by 8.8% to $284 million, making up 18.9% of total consolidated sales.

External API Sales: Decreased by 8.3% to ₹494.6 crore during the quarter ended June 2024.

Key Milestones and Achievements

Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, highlighted several recent milestones, including the approval of Leqselvi in the US, the filing of Nidlegy in Europe, and the completion of the acquisition of Taro minority shares. These steps are expected to advance both the company's innovative and generic business offerings, improving patient care.

Financial Highlights

EBITDA: Rose by 8.3% to ₹3,607 crore from ₹3,331.7 crore in the previous year, with an EBITDA margin improvement of 60 basis points to 28.5%.

R&D Investments: Increased to ₹794 crore compared to ₹679.6 crore in Q1FY24. The company's specialty R&D pipeline includes 6 New Active Substances undergoing clinical studies.

Also Read : Dabur India Reports Strong Financial Performance in June Quarter

Product Pipeline

Sun Pharma has a comprehensive product offering in the US market, consisting of 537 approved ANDAs, with filings for 103 ANDAs awaiting US FDA approval, including 28 tentative approvals. Additionally, the portfolio includes 51 approved NDAs and 14 NDAs awaiting US FDA approval. During the quarter, the company filed 1 ANDA and received 3 approvals.

Market Reaction

At 2:35 pm, Sun Pharma shares were trading 1.02% higher at ₹1,735.40 apiece on the BSE. This positive market response reflects investor confidence in the company's growth trajectory and strategic direction.

Sun Pharma's strong Q1 performance and strategic advancements position it well for continued success in the pharmaceutical industry, driving both revenue and profit growth.

Also Read : Adani Enterprises Q1 Results: Two-Fold Surge in Net Profit

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst & Finance Saathi Telegram Channel for Regular Share Market, News & IPO Updates

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX & Upstox.